Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles

Veterinary Immunology and Immunopathology

Volumn 130, Issue 1-2, 2009, Pages 25-34

  Chou, Pei Chung ^a   Chuang, Tien Fu ^a   Jan, Tong Rong ^a   Gion, Hsin Chan ^a   Huang, Yi Chun ^a   Lei, Han Jon ^a   Chen, Win Yin ^a   Chu, Rea Min ^a  

^a Graduate Institute of Veterinary Medicine   (Taiwan)

Author keywords

Canine; Electroporation; Gene therapy; Interleukins; NK cells; Tumor specific cytotoxicity

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL TISSUE; ANIMAL VENEREAL TUMOR; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG DISEASE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-6; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; PLASMIDS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; VENEREAL TUMORS, VETERINARY;

EID: 67349261550     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.01.002     Document Type: Article

References (61)

1. Ahmad M., Rees R.C., and Ali S.A. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 53 (2004) 844-854
2. Akhurst R.J. TGF-beta antagonists: why suppress a tumor suppressor?. J. Clin. Invest. 109 (2002) 1533-1536
3. Archbold J.K., Ely L.K., Kjer-Nielsen L., Burrows S.R., Rossjohn J., McCluskey J., and Macdonald W.A. T cell allorecognition and MHC restriction-a case of Jekyll and Hyde?. Mol. Immunol. 45 (2008) 583-598
4. Bierie B., and Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6 (2006) 506-520
5. Bubenik J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol. Rep. 10 (2003) 2005-2008
6. Castriconi R., Cantoni C., Della Chiesa M., Vitale M., Marcenaro E., Conte R., Biassoni R., Bottino C., Moretta L., and Moretta A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4120-4125
7. Catchpole B., Gould S.M., Kellett-Gregory L.M., and Dobson J.M. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma. J. Small Anim. Pract. 43 (2002) 464-467
8. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29 (2001) 117-129
9. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
10. Diehl S., and Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39 (2002) 531-536
11. Feinberg M.W., Watanabe M., Lebedeva M.A., Depina A.S., Hanai J., Mammoto T., Frederick J.P., Wang X.F., Sukhatme V.P., and Jain M.K. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J. Biol. Chem. 279 (2004) 16388-16393
12. Ferlazzo G., Pack M., Thomas D., Paludan C., Schmid D., Strowig T., Bougras G., Muller W.A., Moretta L., and Munz C. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 16606-16611
13. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., and Antonaci S. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am. J. Pathol. 161 (2002) 183-193
14. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7 (2001) 1118-1122
15. Gorelik L., and Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2 (2002) 46-53
16. Hirano T., Matsuda T., Hosoi K., Okano A., Matsui H., and Kishimoto T. Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2). Immunol. Lett. 17 (1988) 41-45
17. Hoefer M., and Anderer F.A. Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol. Immunother. 41 (1995) 302-308
18. Houssiau F., and Van Snick J. IL6 and the T-cell response. Res. Immunol. 143 (1992) 740-743
19. Hsiao Y.-W., Liao K.-W., Chung T.-F., Liu C.-H., Hsu C.-D., and Chu R.-M. Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol. Immunopathol. 57 (2008) 1091-1104
20. Hsiao Y.W., Liao K.W., Hung S.W., and Chu R.M. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet. Immunol. Immunopathol. 87 (2002) 19-27
21. Hsiao Y.W., Liao K.W., Hung S.W., and Chu R.M. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J. Immunol. 172 (2004) 1508-1514
22. Huang Y.C., Hunga S.W., Jan T.J., Liao K.W., Cheng C.H., Wang Y.S., and Chu R.M. CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J. Leukocyt. Biol. 8 (2008) 1501-1510
23. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther. 8 Suppl. 2 (2006) S2
24. Kitamura H., Kamon H., Sawa S., Park S.J., Katunuma N., Ishihara K., Murakami M., and Hirano T. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 23 (2005) 491-502
25. Kitamura T., Takaku F., and Miyajima A. IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line TF-1. Int. Immunol. 3 (1991) 571-577
26. + T cells. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1969-1974
27. Kobayashi H., Dubois S., Sato N., Sabzevari H., Sakai Y., Waldmann T.A., and Tagaya Y. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105 (2005) 721
28. Lee Y.J., Han Y., Lu H.T., Nguyen V., Qin H., Howe P.H., Hocevar B.A., Boss J.M., Ransohoff R.M., and Benveniste E.N. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158 (1997) 2065-2075
29. Leivonen S.K., and Kahari V.M. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int. J. Cancer 121 (2007) 2119-2124
30. Li C., Guo B., Bernabeu C., and Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc. Res. Tech. 52 (2001) 437-449
31. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., and Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24 (2006) 99-146
32. Lin C.Y., Chuang T.F., Liao K.W., Huang Y.J., Pai C.C., and Chu R.M. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett. 272 (2008) 285-295
33. Lindahl K.F., and Wilson D.B. Histocompatibility antigen-activated cytotoxic T lymphocytes II. Estimates of the frequency and specificity of precursors. J. Exp. Med. 145 (1977) 508-522
34. Liu C.C., Wang Y.S., Lin C.Y., Chuang T.F., Liao K.W., Chi K.H., Chen M.F., Chiang H.C., and Chu R.M. Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. Cancer Immunol. Immunother. 57 (2008) 479-491
35. Lucas M., Schachterle W., Oberle K., Aichele P., and Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007)
36. Maggard M., Meng L., Ke B., Allen R., Devgan L., and Imagawa D.K. Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann. Surg. Oncol. 8 (2001) 32-37
37. Marrack P., and Kappler J. Control of T cell viability. Annu. Rev. Immunol. 22 (2004) 765-787
38. Mule J.J., Custer M.C., Travis W.D., and Rosenberg S.A. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J. Immunol. 148 (1992) 2622-2629
39. Muraoka R.S., Dumont N., Ritter C.A., Dugger T.C., Brantley D.M., Chen J., Easterly E., Roebuck L.R., Ryan S., Gotwals P.J., Koteliansky V., and Arteaga C.L. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109 (2002) 1551-1559
40. Ohta K., Yamagami S., Taylor A.W., and Streilein J.W. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 41 (2000) 2591-2599
41. Pennington D.W., Lopez A.R., Thomas P.S., Peck C., and Gold W.M. Dog mastocytoma cells produce transforming growth factor beta 1. J. Clin. Invest. 90 (1992) 35-41
42. Perera L.P. Interleukin 15: its role in inflammation and immunity. Arch. Immunol. Ther. Exp. (Warsz) 48 (2000) 457-464
43. Rich J., Borton A., and Wang X. Transforming growth factor-beta signaling in cancer. Microsc. Res. Tech. 52 (2001) 363-373
44. Roberts A.B. Molecular and cell biology of TGF-beta. Miner. Electrolyte Metab. 24 (1998) 111-119
45. Rossmanith W., and Schulte-Hermann R. Biology of transforming growth factor beta in hepatocarcinogenesis. Microsc. Res. Tech. 52 (2001) 430-436
46. Scheller J., and Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med. Microbiol. Immunol. (Berl.) 195 (2006) 173-183
47. Schluns K.S., Williams K., Ma A., Zheng X.X., and Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. 168 (2002) 4827-4831
48. Shephard R.J. Cytokine responses to physical activity, with particular reference to IL-6: sources, actions, and clinical implications. Crit. Rev. Immunol. 22 (2002) 165-182
49. Stover D.G., Bierie B., and Moses H.L. A delicate balance: TGF-beta and the tumor microenvironment. J. Cell. Biochem. 101 (2007) 851-861
50. Suzuki K., Nakazato H., Matsui H., Hasumi M., Shibata Y., Ito K., Fukabori Y., Kurokawa K., and Yamanaka H. NK cell-mediated anti-tumor immune response to human prostate cancer cell PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J. Leukoc. Biol. 69 (2001) 531-537
51. Teicher B.A. Transforming growth factor-beta and the immune response to malignant disease. Clin. Cancer Res. 13 (2007) 6247-6251
52. Thomas D.A., and Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 (2005) 369-380
53. Waldmann T.A., Dubois S., and Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14 (2001) 105-110
54. Waldmann T.A., and Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17 (1999) 19-49
55. Walzer T., Dalod M., Robbins S.H., Zitvogel L., and Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 106 (2005) 2252-2258
56. Whitelegg A., and Barber L.D. The structural basis of T-cell allorecognition. Tissue Antigens 63 (2004) 101-108
57. Witham T.F., Villa L., Yang T., Pollack I.F., Okada H., Robbins P.D., and Chambers W.H. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J. Neurooncol. 64 (2003) 63-69
58. Xiong B., Yuan H.Y., Hu M.B., Zhang F., Wei Z.Z., Gong L.L., and Yang G.L. Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. World J. Gastroenterol. 8 (2002) 674-678
59. + T cell contraction during primary infection. J. Immunol. 176 (2006) 507-515
60. Yang T.J., Chandler J.P., and Dunne-Anway S. Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Br. J. Cancer 55 (1987) 131-134
61. Yano T., Ishikura H., Kato H., Ogawa Y., Kondo S., Kato H., and Yoshiki T. Vaccination effect of interleukin-6-producing pancreatic cancer cells in nude mice: a model of tumor prevention and treatment in immune-compromised patients. Jpn. J. Cancer Res. 92 (2001) 83-87